A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
LP002 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which
prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell
activity, thus enhancing immune response and has potential to treat various types of tumors.
In this study, the safety, pharmacokinetics and preliminary efficacy of LP002 for the
treatment of malignant digestive system neoplasms will be evaluated.